We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

39 hedge funds and large institutions have $84.6M invested in Inozyme Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.11% less ownership

Funds ownership: 78.68% → 78.57% (-0.11%)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

17% less funds holding

Funds holding: 47 → 39 (-8)

43% less capital invested

Capital invested by funds: $149M → $84.6M (-$64.8M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

Holders
39
Holders Change
-8
Holders Change %
-17.02%
% of All Funds
0.67%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
2
Increased
12
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$1.74M
2
RSCM
Rock Springs Capital Management
Maryland
+$606K
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$181K
4
BCM
Bridgeway Capital Management
Texas
+$166K
5
Renaissance Technologies
Renaissance Technologies
New York
+$134K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$2.19M
2
BBA
Baker Bros. Advisors
New York
-$510K
3
CA
CHI Advisors
New York
-$136K
4
E
Ergoteles
New York
-$122K
5
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$72.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$9.8M – – –
DTC
2
Deep Track Capital
Connecticut
$8.71M – – –
RSCM
3
Rock Springs Capital Management
Maryland
$7.52M +$606K +167,562 +6%
VA
4
VR Adviser
New York
$7.26M – – –
PBPIA
5
Pivotal bioVenture Partners Investment Advisor
California
$7.13M – – –
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$6.96M +$181K +50,000 +2%
NMC
7
NEA Management Company
Maryland
$6.55M – – –
DM
8
Deerfield Management
New York
$5.6M -$2.19M -605,936 -22%
CA
9
CHI Advisors
New York
$5.35M -$136K -37,525 -2%
Janus Henderson Group
10
Janus Henderson Group
United Kingdom
$3.81M +$1.74M +481,198 +52%
Vanguard Group
11
Vanguard Group
Pennsylvania
$3.6M -$40.4K -11,153 -0.8%
SFM
12
Sphera Funds Management
Israel
$3.15M +$34.2K +9,458 +0.8%
MB
13
MPM BioImpact
Massachusetts
$1.77M -$13.9K -3,836 -0.6%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$1.63M -$1.59K -439 -0.1%
BlackRock
15
BlackRock
New York
$1.15M -$7.56K -2,089 -0.5%
LCM
16
Laurion Capital Management
New York
$728K – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$626K +$60.6K +16,760 +8%
Millennium Management
18
Millennium Management
New York
$456K -$10.5K -2,908 -2%
UOC
19
UBS O'Connor
Illinois
$444K -$21.2K -5,849 -3%
Renaissance Technologies
20
Renaissance Technologies
New York
$416K +$134K +37,100 +31%
BCM
21
Bridgeway Capital Management
Texas
$358K +$166K +46,000 +53%
Walleye Capital
22
Walleye Capital
New York
$315K +$58.2K +16,087 +16%
Citadel Advisors
23
Citadel Advisors
Florida
$297K -$36.8K -10,179 -8%
State Street
24
State Street
Massachusetts
$205K +$98.8K +27,300 +56%
OMC
25
Overbrook Management Corp
New York
$186K – – –
1
2

INZY Hedge Fund Activity: Q3 2022 in Review

39 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2022, worth a combined $84.6M — down 43% from $149M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of INZY and 2 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 12 added.

The largest buyer was Janus Henderson Group, adding an estimated $1.74M. The largest seller was Deerfield Management, cutting an estimated $2.19M.

  • 39 institutional investors held Inozyme Pharma (INZY) as of Q3 2022, down from 47 in Q2 2022.
  • Funds reported $84.6M of Inozyme Pharma stock for Q3 2022, down 43% quarter-over-quarter.
  • 2 funds opened new Inozyme Pharma positions in Q3 2022 and 10 closed out, a net change of -8 holders.
  • The largest Inozyme Pharma buyer in Q3 2022 was Janus Henderson Group, an estimated $1.74M added.
  • The largest Inozyme Pharma seller in Q3 2022 was Deerfield Management, an estimated $2.19M sold.

Based on aggregated 13F filings for Q3 2022.